PET for Drug Development and Evaluation

edited by

D. COMAR

Hôpital Neuro-cardiologique,
Lyon, France
**TABLE OF CONTENTS**

**Part one: Introduction**

1. Drug development and positron emission tomography  
   B. Campbell  
   1

2. Positron emission tomography: Basic principles and potential interest for pharmacological studies  
   B. Mazoyer  
   25

3. Is PET a tool for drug evaluation?  
   B. Långström, M. Bergström, P. Hartvig, S. Valind and Y. Watanabe  
   37

**Part two: Psychiatry**

4. PET in neuropsychiatric drug development  
   L. Farde  
   51

5. Radioligand disposition and metabolism - Key information in early drug development  
   C. Halldin, C.-G. Swahn, L. Farde and G. Sevcall  
   55

6. PET studies in the early clinical development of a new antipsychotic  
   J.M.A. Sitsen and L. Farde  
   67

7. PET in the development of Dopamine D1 antagonists as new potential antipsychotic drugs  
   C. Foged, P. Karlsson, B.K. Skrumsager, L. Ynndal, E.B. Nielsen, C. Halldin and L. Farde  
   73

8. Is the 5-HT₂-receptor a target for antipsychotic drug action? PET studies on dopamine (D₂) and serotonin (5-HT₂) receptor occupancy in patients and healthy subjects  
   S. Nyberg, A.-L. Nordström, C. Halldin and L. Farde  
   83
9. Preclinical development of a radioligand for the study of central 5-HT_{1A} receptors with PET-[11C]WAY-100635

10. Comparative in vivo and in vitro selectivity of zolpidem for ω (Benzodiazepine) modulatory site subtypes
J. Benavides, P. Abadie, J.C. Baron and B. Scatton

11. Do the effects of muscarinic receptor blockade on brain glucose consumption mimic the cortical and subcortical metabolic pattern of Alzheimer’s disease in normal volunteers?
J. Blin, T.N. Chase and M.F. Piercey

Part three: Neurology

12. PET evaluation of drug treatment in ischemic stroke and Alzheimer’s disease
W.-D. Heiss

13. PET imaging of cerebral perfusion and oxygen metabolism in acute ischemic stroke: Implications for management and therapy
J.C. Baron

14. Pharmacokinetics: Kinetic modelling of MAO inhibitors and D₂ antagonists
A. Lammertsma and C.J. Bench

15. Brain activation under drug treatment
P.M. Grasby and K.J. Friston

16. Modifying the progression of Parkinson’s disease
P. Morrish, J. Rakshi and D.J. Brooks

17. COMT inhibition: Pharmacology of tolcapone and 6-[¹⁸F]-Fluoro-L-Dopa (FDOPA) PET results
K. Jorga, K.L. Leenders, I. Günther and M. Psylla

18. Interaction of Lisuride with dopaminergic receptors
B. Maizière and R. Horowski

19. Lisuride and [C-11]-raclopride interaction at the D2 receptor site
K.L. Leenders and A. Antonini
Part four: Cardiology

20. Drug design in cardiology: The pharmaceutical industry point of view
   R. Gradnik
   215

21. Myocardial receptors and their interaction with cardiovascular drugs
   A. Syrota and P. Merlet
   219

22. The pathophysiological background of cardiovascular diseases and its impact
    on diagnosis and treatment
   P.G. Camici
   233

23. Effect of cardiotonic drugs on myocardial oxygen consumption and efficiency
    as assessed by $^{11}$C-acetate and PET
   253

24. Integration of new and classical techniques in drug development. PET
    application to Propionyl-L-carnitine pharmacokinetic study
   A. Longo, F. Fiore, M.P. Law, A. Mancinelli, V. Pike and P.G. Camici
   263

Part five: Oncology

25. The view of the EORTC new drug development office on PET in (pre)clinical
    trials of anticancer drugs
   H.R. Hendriks and J. Wanders
   267

    pharmacokinetic and pharmacodynamic issues and the potential role of PET
   P. Workman
   277

27. Radiolabelled anticancer drugs for in vivo pharmacokinetic studies by PET
   W. Vaalburg and F. Brady
   287

28. The use of radiolabelled anticancer drugs in phase I/II clinical trials and the
    assessment of therapeutic efficacy of new agents using PET
   P. Price, R. Harte, O. Tilsley, J. Matthews, F. Brady, S. Luthra, S. Osman,
   R. Babarovic, G. Brown, S. O'Reilly, C. Brock, P. Wells and T. Jones
   301

29. Kinetics and applications of F-18-fluorouracil in colorectal tumors
   L.G. Strauss
   327
30. The disposition of a new drug propellant (HFA 134a) in humans studied by fluorine-18 labelling and whole-body γ-counting

31. Preclinical characterisation of radiolabelled idoxifene
P. Carnochan, H. Young, M. Trivedi, S. Eccles, B. Haynes and G. Potter